Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Osteoarthritis “Medical Food” Limbrel Tied to Life-Threatening Events

November 28, 2017 By Law Offices of Thomas J. Lamb, P.A.


What is Limbrel?

Limbrel is marketed by Primus Pharmaceuticals Inc., and is classified as a “medical food,” which the FDA defines as:

A food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.

More specifically, Limbrel is a flavonoid capsule that contains baicalin, catechin, and zinc, and comes in two different dosages.  It is intended to manage the nutritional requirements and metabolic processes of osteoarthritis patients.

 

FDA Warning

On November 21, the FDA announced that it is currently investigating the association between Limbrel and two potentially life-threatening conditions: drug-induced liver injury and hypersensitivity pneumonitis.  That safety alert from the FDA provided the following information:

In total, the FDA has received 194 adverse event reports regarding Limbrel, of those, 57 of the cases contained sufficient information to analyze in detail whether Limbrel was associated with an adverse event; 30 of these contained sufficient information to use the Council for International Organizations of Medical Sciences (CIOMS) causality assessment method to determine the likelihood that an association between the consumption of Limbrel and the adverse events reported exists.

Primus Pharmaceuticals has provided information to the FDA regarding the formula and manufacturing process for Limbrel, which are currently being reviewed.

In the meantime, the FDA encouraged those taking Limbrel to stop immediately and contact their doctor.  In addition, they recommend reporting any adverse side effects from Limbrel through the FDA MedWatch reporting system.

 

Going Forward

It will be interesting to see whether the Limbrel package insert and FDA warnings for Limbrel are altered to include drug-induced liver injury and hypersensitivity pneumonitis.

We will continue to monitor the medical literature concerning Limbrel’s association with these side effects, report on the FDA’s findings from its research on Limbrel’s formula and its manufacturing process.

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.

 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

 

Filed Under: Unsafe Drugs Tagged With: baicalin, catechin, drug safety communication, FDA, FDA investigation, FDA MedWatch reporting system, flavonoid capsule, limbrel, medical food, osteoarthritis, osteoarthritis drugs, Primus Pharmaceuticals

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.